Related Experiment Video
Updated: Jun 21, 2026
09:05
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
Published on: August 9, 2017
Growth-differentiation factor-15 in heart failure.
1Hannover Medical School, Hannover, Germany.
Heart Failure Clinics
|July 28, 2009
Summary
Growth-differentiation factor-15 (GDF-15) is a new biomarker for cardiovascular disease. Elevated GDF-15 levels indicate a worse prognosis in acute coronary syndrome and heart failure, aiding risk stratification.
Area of Science:
- Cardiology
- Biomarkers
- Molecular Medicine
Background:
- Growth-differentiation factor-15 (GDF-15) is a stress-responsive cytokine.
- GDF-15 is emerging as a significant biomarker in cardiovascular disease.
- Elevated GDF-15 levels correlate with adverse outcomes in acute coronary syndrome and heart failure.
Purpose of the Study:
- To evaluate the prognostic value of GDF-15 in cardiovascular disease.
- To determine if GDF-15 provides additional information beyond established risk markers.
- To explore the potential of GDF-15 in guiding treatment strategies.
Main Methods:
- Analysis of circulating GDF-15 levels in patients with cardiovascular conditions.
- Correlation of GDF-15 levels with clinical outcomes and established risk markers.
- Investigation of GDF-15's role in specific patient subgroups, such as non-ST-elevation acute coronary syndrome.
Main Results:
- Circulating GDF-15 levels are elevated in patients with acute coronary syndrome and heart failure.
- Elevated GDF-15 is independently associated with an adverse prognosis.
- GDF-15 offers significant prognostic value, enhancing existing risk assessment tools.
Conclusions:
- GDF-15 is a valuable prognostic biomarker in acute coronary syndrome and heart failure.
- Elevated GDF-15 may identify non-ST-elevation acute coronary syndrome patients who benefit most from invasive strategies.
- Further research into GDF-15's pathobiology is needed to develop targeted therapies for cardiovascular risk.
More Related Videos
08:37Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells
Published on: June 19, 2018
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...